Growth Metrics

Oculis Holding AG (OCS) Equity Ratio (2021 - 2025)

Quarterly Equity Ratio fell 32.98% to 248.72 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 248.72 through Dec 2025, down 32.98% year-over-year, with the annual reading at 248.72 for FY2025, 32.98% down from the prior year.

Oculis Holding AG's Equity Ratio history spans 5 years, with the latest figure at 248.72 for Q4 2025.

  • Equity Ratio came in at 248.72 for Q4 2025, down from 371.1 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 371.1 in Q4 2024 to a low of 2.64 in Q4 2022.
  • The 5-year median for Equity Ratio is 248.72 (2025), against an average of 187.32.
  • Year-over-year, Equity Ratio tumbled 151.78% in 2022 and then surged 12221.1% in 2023.
  • Oculis Holding AG's Equity Ratio stood at 1.05 in 2021, then crashed by 151.78% to 2.64 in 2022, then surged by 12221.1% to 320.5 in 2023, then grew by 15.79% to 371.1 in 2024, then tumbled by 32.98% to 248.72 in 2025.
  • Per Business Quant, the three most recent readings for OCS's Equity Ratio are 248.72 (Q4 2025), 371.1 (Q4 2024), and 320.5 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 0.04
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 0.42
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.73
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.77
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.21
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 248.72
Dec 31, 2024 371.10
Dec 31, 2023 320.50
Dec 31, 2022 -2.64
Dec 31, 2021 -1.05